Products and Services

Aptar Pharma announced that it has acquired OINDP specialist CDMO Mod3 Pharma (formerly Enteris Biopharma). According to Mod3’s web site, Enteris was created in 2013 with assets and personnel from Unigene, which manufactured Fortical calcitonin… Read more . . .

German startup Ebenbuild has received a €2.3 million grant plus a commitment for up to an additional €10 million in future investments from the European Innovation Council (EIC) Accelerator program, the company said. The funding… Read more . . .

CDMO Kindeva has announced an agreement with Canadian company Rocket Science Health (RSH) for development of RSH’s “Olfactory Delivery Device,” which is designed for high deposition of drug to the olfactory clefts. Kindeva, which acquired nasal… Read more . . .

Aptar CSP Technologies has announced an expansion of its cGMP manufacturing capacity for clinical packaging of dry powder inhalation capsules using the company’s Activ-Blister technology. Aptar CSP cited growing demand for the technology for both… Read more . . .

3P innovation has announced that it is now offering new filling technology in its custom-built DPI filling systems that is based on equipment originally patented by GSK for high-speed filling of Diskus dry powder inhalers.… Read more . . .

Intertek has announced a 6,000 sq ft expansion of its facility in Melbourn, UK to add laboratory space for characterization of large molecules for inhalation. In 2019, the company acquired a facility that doubled its… Read more . . .

Inhalation CDMO Bespak announced that it has completed an independently verified life cycle assessment to evaluate environmental impacts associated with materials and manufacturing of its BK357 metered dose inhaler valve. The company said that the assessment… Read more . . .

Swedish DPI developer Iconovo has announced that it will lay off about 10 employees as it switches its focus to commercialization of its existing dry powder inhalation platforms, including the ICOres reservoir-based DPI, the ICOpre… Read more . . .

AptarGroup announced that its subsidiary Nanopharm is initiating a clinical study to validate the SmartTrack in-vitro-in-silico modeling platform as an alternative to clinical endpoint studies for determining bioequivalence of inhaled drug products. The study will… Read more . . .